losartan has been researched along with Glomerulosclerosis, Focal Segmental in 23 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Glomerulosclerosis, Focal Segmental: A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment." | 9.10 | Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003) |
| " The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment." | 5.10 | Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003) |
| "We report three cases of focal glomerular sclerosis (FGS) with proteinuria that improved with the administration of angiotensin type 1 receptor blocker (ARB, losartan or valsartan)." | 3.72 | [Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis]. ( Chihara, Y; Fujimori, T; Iidaka, K; Inada, H; Ishimitsu, T; Matsuoka, H; Ogihara, T; Ono, H; Ono, Y; Rakugi, H; Ueda, Y, 2004) |
| " Both captopril treatment and losartan treatment completely blocked the development of hypertension in diabetic SHR." | 3.69 | Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. ( Abe, K; Fu, LP; Kanazawa, M; Kohzuki, M; Obara, K; Saito, T; Yasujima, M; Yoshida, K, 1995) |
| "The Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) project is a multicenter Phase I/II RCT designed to investigate the potential efficacy of novel therapies for resistant FSGS." | 2.76 | Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. ( Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L, 2011) |
| "The rat model of diabetic nephropathy was established by streptozotozin(STZ) injection, and the rats were randomly divided into 3 groups: (a normal group, a model group and a losartan group)." | 1.35 | [The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy]. ( Liu, JS; Ning, WB; Tao, LJ; Wang, L; Xu, JY, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| van Thiel, BS | 1 |
| van der Linden, J | 1 |
| Ridwan, Y | 1 |
| Garrelds, IM | 1 |
| Vermeij, M | 1 |
| Clahsen-van Groningen, MC | 1 |
| Qadri, F | 1 |
| Alenina, N | 1 |
| Bader, M | 1 |
| Roks, AJM | 1 |
| Danser, AHJ | 1 |
| Essers, J | 1 |
| van der Pluijm, I | 1 |
| Toba, H | 1 |
| Ikemoto, MJ | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Shiozaki, Y | 1 |
| Fujikura, T | 1 |
| Isobe, S | 1 |
| Takatsuka, I | 1 |
| Sato, T | 1 |
| Goto, D | 1 |
| Ishigaki, S | 1 |
| Ohashi, N | 1 |
| Yasuda, H | 1 |
| Awazu, M | 1 |
| Yamada, M | 1 |
| Asada, N | 1 |
| Hashiguchi, A | 1 |
| Kosaki, K | 1 |
| Matsumura, K | 1 |
| Ávila, VF | 1 |
| Foresto-Neto, O | 1 |
| Arias, SCA | 1 |
| Faustino, VD | 1 |
| Malheiros, DMAC | 1 |
| Camara, NOS | 1 |
| Zatz, R | 3 |
| Fujihara, CK | 3 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Eroglu, E | 1 |
| Unal, A | 1 |
| Sipahioglu, MH | 1 |
| Berk, V | 1 |
| Tokgoz, B | 1 |
| Oymak, O | 1 |
| Fervenza, FC | 1 |
| Perazella, MA | 1 |
| Choi, MJ | 1 |
| Xu, JY | 1 |
| Tao, LJ | 1 |
| Wang, L | 1 |
| Ning, WB | 1 |
| Liu, JS | 1 |
| Gupta, A | 1 |
| Gaikwad, J | 1 |
| Khaira, A | 1 |
| Rana, DS | 1 |
| Trachtman, H | 1 |
| Vento, S | 1 |
| Gipson, D | 1 |
| Wickman, L | 1 |
| Gassman, J | 1 |
| Joy, M | 1 |
| Savin, V | 1 |
| Somers, M | 1 |
| Pinsk, M | 1 |
| Greene, T | 1 |
| Grosch, S | 1 |
| Van Overmeire, L | 1 |
| Krzesinski, JM | 1 |
| Bovy, C | 1 |
| Saeed, B | 1 |
| Mazloum, H | 1 |
| Askar, M | 1 |
| Yuan, SG | 1 |
| Liu, RH | 1 |
| Xia, YC | 1 |
| Bertram, D | 1 |
| Blanc-Brunat, N | 1 |
| Sassard, J | 1 |
| Lo, M | 1 |
| Usta, M | 1 |
| Ersoy, A | 1 |
| Dilek, K | 1 |
| Ozdemir, B | 1 |
| Yavuz, M | 1 |
| Güllülü, M | 1 |
| Yurtkuran, M | 1 |
| Aunapuu, M | 1 |
| Pechter, U | 1 |
| Arend, A | 1 |
| Suuroja, T | 1 |
| Ots, M | 1 |
| Kim, HJ | 1 |
| Ryu, JH | 1 |
| Han, SW | 1 |
| Park, IK | 1 |
| Paik, SS | 1 |
| Park, MH | 1 |
| Paik, DJ | 1 |
| Chung, HS | 1 |
| Kim, SW | 1 |
| Lee, JU | 1 |
| Chihara, Y | 1 |
| Ono, H | 1 |
| Ono, Y | 1 |
| Inada, H | 1 |
| Ueda, Y | 1 |
| Fujimori, T | 1 |
| Iidaka, K | 1 |
| Ishimitsu, T | 1 |
| Rakugi, H | 1 |
| Ogihara, T | 1 |
| Matsuoka, H | 1 |
| Ji, Z | 1 |
| Huang, C | 1 |
| Liang, C | 1 |
| Chen, B | 1 |
| Chen, S | 1 |
| Sun, W | 1 |
| Malheiros, DM | 1 |
| De Nucci, G | 1 |
| Kohzuki, M | 1 |
| Yasujima, M | 1 |
| Kanazawa, M | 1 |
| Yoshida, K | 1 |
| Fu, LP | 1 |
| Obara, K | 1 |
| Saito, T | 1 |
| Abe, K | 1 |
| Bidani, AK | 1 |
| Griffin, KA | 1 |
| Bakris, G | 1 |
| Picken, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Novel Therapies for Resistant Focal Segmental Glomerulosclerosis[NCT00814255] | Phase 2 | 32 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System[NCT02235857] | 35 participants (Anticipated) | Interventional | 2015-05-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with a reduction in proteinuria at 6 months by > 50% of the value at screening AND stable GFR defined as greater than 75 ml/min/1.73m2 in those with an initial value above 90 OR within 25% of baseline for remaining patients. (NCT00814255)
Timeframe: baseline and 6 months
| Intervention | participants (Number) |
|---|---|
| Conservative Medical Therapy Plus Adalimumab | 0 |
| Conservative Medical Therapy (Lisinopril, Losartan, Atorvastat | 2 |
| Conservative Medical Therapy Plus Galactose | 2 |
(NCT00814255)
Timeframe: Up to 7 months
| Intervention | participants (Number) |
|---|---|
| Conservative Medical Therapy Plus Adalimumab | 7 |
| Conservative Medical Therapy (Lisinopril, Losartan, Atorvastat | 7 |
| Conservative Medical Therapy Plus Galactose | 7 |
2 trials available for losartan and Glomerulosclerosis, Focal Segmental
| Article | Year |
|---|---|
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Azathioprine; Blood Pressure; Cyclophospham | 2003 |
21 other studies available for losartan and Glomerulosclerosis, Focal Segmental
| Article | Year |
|---|---|
In Vivo Renin Activity Imaging in the Kidney of Progeroid
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA | 2021 |
Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats.
Topics: ADAMTS1 Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone Acetate; Ext | 2022 |
Case report: increased single-nephron estimated glomerular filtration rate in an adult patient with low birth weight.
Topics: Angiotensin II Type 1 Receptor Blockers; Cell Count; Female; Glomerular Filtration Rate; Glomerulosc | 2020 |
A girl with a mutation of the ciliary gene CC2D2A presenting with FSGS and nephronophthisis.
Topics: Child; Child, Preschool; Cytoskeletal Proteins; Female; Fibrosis; Glomerulosclerosis, Focal Segmenta | 2022 |
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Female; G | 2019 |
Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma.
Topics: Adenocarcinoma; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Edema; Glomerulonephri | 2013 |
American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antibodies, Monoclonal, Mur | 2014 |
[The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy].
Topics: Animals; Collagen Type IV; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabeti | 2008 |
Marfan syndrome and focal segmental glomerulosclerosis: a novel association.
Topics: Adolescent; Adrenal Cortex Hormones; Antihypertensive Agents; Fibrillins; Follow-Up Studies; Glomeru | 2010 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; G | 2011 |
Spontaneous remission of post-transplant recurrent focal and segmental glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Pr | 2011 |
[Effects on ang II receptor antagonist on experimental glomerulosclerosis].
Topics: Angiotensin Receptor Antagonists; Animals; Blood Urea Nitrogen; Glomerulosclerosis, Focal Segmental; | 2000 |
Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2002 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2004 |
[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diet, Protein-Restricted; D | 2004 |
Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Seq | 2005 |
Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Diuretics | 2007 |
Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy.
Topics: Amino Acid Oxidoreductases; Angiotensin Receptor Antagonists; Animals; Arginine; Biphenyl Compounds; | 1995 |
Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Captopril; Diabetes M | 1995 |
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pres | 2000 |